However, the first-in-class inhibitor of the ASH1L SET domain, AS-99, has shown remarkable anti-leukemic activity (34) against MLL1 fusion leukemia, suggesting that ASH1L can be potentially targeted for the therapeutic cancer treatment. This evidence concerns the gene ASH1L and cancer.